Today, 15 July 2020, the European Association for Haemophilia and Allied Disorders together with 69 other thrombosis, haematology and patient safety organisations, published a Consensus Statement on the increased risk of deadly blood clots in Covid-19 patients.

The 2019 EAHAD Annual Report has just been published. In it, readers will find information on all EAHAD-related activities of the past year.

The European Association for Haemophilia and Allied Disorders (EAHAD) and European Haemophilia Consortium (EHC) have become aware of two deaths in patients with X-linked myotubular myopathy (XLMTM) on an AAV8-based gene therapy (AT132) in the phase 1/2 ASPIRO clinical trial conducted by Audentes, a subsidiary of Astellas. EHC and EAHAD are closely monitoring developments in this area due to this adeno-associated viral vector (AAV8) also being used in haemophilia gene therapy trials.

The Covid-19 pandemic has caused a multi-dimensional crisis: medical, psychological, economic, occupational, and educational and more. People with bleeding disorders have suffered anxiety and concern regarding the influence of Covid-19 on their condition as well as uncertainty as to whether their treatments will continue to be accessible during this pandemic.

Hosted by Prof. Michael Makris and with three insightful presentations by Prof. Víctor Jiménez Yuste, Prof. Flora Peyvandi, and Prof. Cedric Hermans, the EAHAD Webinar on Covid-19 and Haemophilia (originally streamed on Tuesday 2 June 2020) is now available for everyone to watch.

By Dr Sébastien Lobet, EAHAD Physiotherapists Committee past Chair   Dear Piet,

By Paul McLaughlin, EAHAD Physiotherapists Committee Vice-Chair   The 14th annual general meeting of the UK Haemophilia Chartered Physiotherapists Association (HCPA) was held on 5 and 6 March 2020.

  On 4 February 2020 in The Hague, Netherlands, the Physiotherapists Committee welcomed colleagues from Europe and around the world to the EAHAD Multidisciplinary Pre-Congress Day physiotherapy sessions.

For the past three decades, haemophilia A and B have been treated using FVIII and FIX replacement concentrates, and their treatment and care has been managed through comprehensive or standard haemophilia treatment centres.